Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04146896 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)
A Phase 2 study, sponsored by Aptinyx.
- Completed
- Registry status
- Phase 2
- Development phase
- 228
- Enrollment target
NCT04146896: Completed Phase 2 study, sponsored by Aptinyx.
NCT04146896 is a Phase 2 study that has completed, run by Aptinyx. The registered enrollment target is 228 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04146896, a Phase 2 study, has completed, sponsored by Aptinyx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 228 participants
- Enrollment target
Study Summary
To evaluate the efficacy of NYX-2925 versus placebo in treating the neuropathic pain associated with diabetic peripheral neuropathy.
Primary Outcome
Change from baseline in the weekly mean of the daily Numeric Rating Scale (NRS) score assessing average pain intensity related to DPN in the past 24 hours. In the NRS, a participant selects a whole number (0 to 10) that best indicates the intensity of his/her pain, where 0 represents no pain and 10 represents worst pain imaginable.
Interventions
- DRUG Placebo
- DRUG NYX-2925 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2019-11-12 |
| Est. Completion | 2022-02-23 |
| Phase | Phase 2 |
What the finished NCT04146896 record still lists
NCT04146896 is an interventional study that assigns participants to a tested intervention. The registered 228 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04146896 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04146896 about?
NCT04146896 is a clinical study titled "Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)". To evaluate the efficacy of NYX-2925 versus placebo in treating the neuropathic pain associated with diabetic peripheral neuropathy.
What is the current status of trial NCT04146896?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 228 participants. The study started on 2019-11-12. Estimated completion is 2022-02-23.
What interventions are being tested in trial NCT04146896?
The interventions under investigation include: Placebo (DRUG), NYX-2925 50 mg (DRUG).
Who is sponsoring clinical trial NCT04146896?
This trial is sponsored by Aptinyx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04146896's enrollment target sits among peer trials
228 264th of 2000 higher than 1,736 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
- NCT05547698 · 228 participants · NA
A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation
- NCT05630963 · 228 participants
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
- NCT06073665 · 228 participants · Phase 4
Dosing of LT4 in Older Individuals
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI